The future of immunotherapy for sarcoma

References

• McCarthy E. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J. 2006;26:154–158.
   PubMedGoogle Scholar
• Marcove RC, Mike V, Huvos AG, et al. Vaccine trials for osteogenic sarcoma. A preliminary report. CA Cancer J Clin. 1973;23(2):74–80.
   PubMedGoogle Scholar
• Marcove RC. A clinical trial of autogenous vaccines in the treatment of osteogenic sarcoma. Beitr Pathol. 1974;153(1):65–72.
   PubMedGoogle Scholar
• Friedman MA, Carter SK. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol. 1972;4(5):482–510.
   PubMedGoogle Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49(6):1221–1230.
   PubMed Web of Science ®Google Scholar
• Iwamoto Y. Diagnosis and treatment of Ewing’s sarcoma. Jpn J Clin Oncol. 2007;37(2):79–89.
   PubMed Web of Science ®Google Scholar
• Hosoi H. Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan. Pediatr Int. 2016;58(2):81–87.
   PubMed Web of Science ®Google Scholar
• The JOA Musculo-Skeletal Tumor Comittee. General rules for clinical and pathological studies on malignant bone tumors. Tokyo: Kanabara; 2000.
   Google Scholar
• Springfield DS, Schmidt R, Graham-Pole J, et al. Surgical treatment for osteosarcoma. J Bone Joint Surg Am. 1988;70(8):1124–1130.
   PubMed Web of Science ®Google Scholar
• Kapalschinski N, Goertz O, Harati K, et al. Plastic surgery in the multimodal treatment concept of soft tissue sarcoma: influence of radiation, chemotherapy, and isolated limb perfusion on plastic surgery techniques. Front Oncol. 2015;5:268.
   PubMed Web of Science ®Google Scholar
• Groundland JS, Binitie O. Reconstruction after tumor resection in the growing child. Orthop Clin North Am. 2016;47(1):265–281.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Chintagumpala M. Targeted therapy in bone and soft tissue sarcoma in children and adolescents. Curr Oncol Rep. 2012;14(2):197–205.
   PubMed Web of Science ®Google Scholar
• Isakoff MS, Bielack SS, Meltzer P, et al. Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol. 2015;33(27):3029–3035.
   PubMed Web of Science ®Google Scholar
• Linehan DC, Bowne WB, Lewis JJ. Immunotherapeutic approaches to sarcoma. Semin Surg Oncol. 1999;17(1):72–77.
   PubMedGoogle Scholar
• Burgess M, Tawbi H. Immunotherapeutic approaches to sarcoma. Curr Treat Options Oncol. 2015;16(6):26.
   PubMed Web of Science ®Google Scholar
• Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61(23):8513–8519.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high risk pediatric sarcomas. Clin Cancer Res. 2016 Jan 28. [Epub ahead of print]
   Google Scholar
• Cripe TP, Ngo MC, Geller JI, et al. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients. Mol Ther. 2015;23(3):602–608.
   PubMed Web of Science ®Google Scholar
• Himoudi N, Wallace R, Parsley KL, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol. 2012;14(4):271–279.
   PubMed Web of Science ®Google Scholar
• Dagher R, Long LM, Read EJ, et al. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: an inter-institute NIH study. Med Pediatr Oncol. 2002;38(3):158–164.
   PubMedGoogle Scholar
• Mackall CL, Rhee EH, Read EJ, et al. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res. 2008;14(15):4850–4858.
   PubMed Web of Science ®Google Scholar
• Ullenhag GJ, Spendlove I, Watson NF, et al. T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin Immunol. 2008;128(2):148–154.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7):917–924.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21(5):1019–1027.
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Tsukahara T, Ida K, et al. SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: a study from the Japanese musculoskeletal oncology group. Cancer Sci. 2012;103(9):1625–1630.
   PubMed Web of Science ®Google Scholar
• Takahashi R, Ishibashi Y, Hiraoka K, et al. Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients. Cancer Sci. 2013;104(10):1285–1294.
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Shusterman S, Bai F, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015;64(10):1251–1260.
   PubMed Web of Science ®Google Scholar
• Goldberg JM, Fisher DE, Demetri GD, et al. Biologic activity of autologous, granulocyte-macrophage colony-stimulating factor secreting alveolar soft-part sarcoma and clear cell sarcoma vaccines. Clin Cancer Res. 2015;21(14):3178–3186.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Torigoe T, Tamura Y, et al. Antigenic peptide vaccination: provoking immune response and clinical benefit for cancer. Curr Immunol Rev. 2008;4:235–241.
   Google Scholar
• Sato Y, Nabeta Y, Tsukahara T, et al. Detection and induction of CTLs specific for SYT-SSX-derived peptides in HLA-A24(+) patients with synovial sarcoma. J Immunol. 2002;169(3):1611–1618.
   PubMed Web of Science ®Google Scholar
• Ida K, Kawaguchi S, Sato Y, et al. Crisscross CTL induction by SYT-SSX junction peptide and its HLA-A*2402 anchor substitute. J Immunol. 2004;173(2):1436–1443.
   PubMed Web of Science ®Google Scholar
• Kawaguchi S, Wada T, Ida K, et al. Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma. J Transl Med. 2005;3(1):1.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Nabeta Y, Kawaguchi S, et al. Identification of human autologous cytotoxic T-lymphocyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res. 2004;64(15):5442–5448.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic impact and immunogenicity of a novel osteosarcoma antigen, papillomavirus binding factor, in patients with osteosarcoma. Cancer Sci. 2008;99(2):368–375.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Torigoe T, et al. HLA-A*0201-restricted CTL epitope of a novel osteosarcoma antigen, papillomavirus binding factor. J Transl Med. 2009;7:44.
   PubMed Web of Science ®Google Scholar
• Lee JS, DuBois SG, Boscardin WJ, et al. Secondary malignant neoplasms among children, adolescents, and young adults with osteosarcoma. Cancer. 2014;120(24):3987–3993.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the children’s oncology group. J Clin Oncol. 2008;26(4):633–638.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850–854.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer. 2003;3(9):666–675.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299–308.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126–129.
   PubMed Web of Science ®Google Scholar
• Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3):620–626.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther. 2014;21(2):45–47.
   PubMed Web of Science ®Google Scholar
• Lu YC, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22–27.
   Google Scholar
• Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641–645.
   PubMed Web of Science ®Google Scholar
• Murase M, Kano M, Tsukahara T, et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer. 2009;101:1425–1432.
   PubMed Web of Science ®Google Scholar
• Kano M, Tsukahara T, Emori M, et al. Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma. Cancer Sci. 2011;102(8):1443–1447.
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Inoda S, et al. Cytotoxic T lymphocytes: sniping cancer stem cells. Oncoimmunology. 2012;1(1):123–125.
   PubMed Web of Science ®Google Scholar
• Emori M, Tsukahara T, Murase M, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8(12):e84187.
   PubMed Web of Science ®Google Scholar
• Singh N, Frey NV, Grupp SA, et al. CAR T cell therapy in acute lymphoblastic leukemia and potential for chronic lymphocytic leukemia. Curr Treat Options Oncol. 2016;17(6):28.
   PubMedGoogle Scholar
• Klebanoff CA, Rosenberg SA, Restifo NP. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med. 2016;22(1):26–36.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133.
   PubMed Web of Science ®Google Scholar
• Weinstock M, McDermott D. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther Adv Urol. 2015;7(6):365–377.
   PubMed Web of Science ®Google Scholar
• Garon EB. Current perspectives in immunotherapy for non-small cell lung cancer. Semin Oncol. 2015;42(Suppl 2):S11–S18.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Robbins PF, Lu YC, El-Gamil M, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013;19(6):747–752.
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF, et al. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med. 1996;183(3):1185–1192.
   PubMed Web of Science ®Google Scholar
• Coulie PG, Lehmann F, Lethe B, et al. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci U S A. 1995;92(17):7976–7980.
   PubMed Web of Science ®Google Scholar
• Chiari R, Foury F, De Plaen E, et al. Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene. Cancer Res. 1999;59(22):5785–5792.
   PubMed Web of Science ®Google Scholar
• Baurain JF, Colau D, Van Baren N, et al. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J Immunol. 2000;164(11):6057–6066.
   PubMed Web of Science ®Google Scholar
• Wolfel T, Hauer M, Schneider J, et al. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 1995;269(5228):1281–1284.
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Brasseur F, Andry G, et al. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med. 1997;186(5):785–793.
   PubMed Web of Science ®Google Scholar
• Gueguen M, Patard JJ, Gaugler B, et al. An antigen recognized by autologous CTLs on a human bladder carcinoma. J Immunol. 1998;160(12):6188–6194.
   PubMed Web of Science ®Google Scholar
• Brandle D, Brasseur F, Weynants P, et al. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J Exp Med. 1996;183(6):2501–2508.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Wang X, Shofuda T, et al. Isolation of a new melanoma antigen, MART-2, containing a mutated epitope recognized by autologous tumor-infiltrating T lymphocytes. J Immunol. 2001;166(4):2871–2877.
   PubMed Web of Science ®Google Scholar
• Wang RF, Wang X, Atwood AC, et al. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science. 1999;284(5418):1351–1354.
   PubMed Web of Science ®Google Scholar
• Echchakir H, Mami-Chouaib F, Vergnon I, et al. A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma. Cancer Res. 2001;61(10):4078–4083.
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189–2199.
   PubMed Web of Science ®Google Scholar
• Yadav M, Jhunjhunwala S, Phung QT, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014;515(7528):572–576.
   PubMed Web of Science ®Google Scholar
• Pritchard AL, Burel JG, Neller MA, et al. Exome sequencing to predict neoantigens in melanoma. Cancer Immunol Res. 2015;3(9):992–998.
   PubMed Web of Science ®Google Scholar
• Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463–1469.
   PubMed Web of Science ®Google Scholar
• Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.
   PubMedGoogle Scholar
• D’Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46(3):357–365.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Kawaguchi S, Torigoe T, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Sci. 2006;97(12):1374–1380.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2(7):690–698.
   PubMed Web of Science ®Google Scholar
• Schmerling RA. Toxicity of checkpoint inhibitors. Chin Clin Oncol. 2014;3(3):31.
   PubMedGoogle Scholar
• Khoja L, Atenafu EG, Ye Q, et al. Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett. 2016;11(2):1581–1585.
   PubMed Web of Science ®Google Scholar
• Ciccarese C, Alfieri S, Santoni M, et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016;12(1):57–75.
   PubMed Web of Science ®Google Scholar
• Yamazaki N, Kiyohara Y, Uhara H, et al. Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. Cancer Chemother Pharmacol. 2015;76(5):997–1004.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Tsuruma T, Iwayama Y, Ohmura T, et al. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer. J Transl Med. 2008;6(1):24.
   PubMed Web of Science ®Google Scholar
• Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8(6):1731–1739.
   PubMed Web of Science ®Google Scholar
• Kameshima H, Tsuruma T, Kutomi G, et al. Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013;104(1):124–129.
   PubMed Web of Science ®Google Scholar
• Ogihara Y, Takeda K, Yanagawa T, et al. Spontaneous regression of lung metastases from osteosarcoma. Cancer. 1994;74(10):2798–2803.
   PubMed Web of Science ®Google Scholar
• Slovin SF, Lackman RD, Ferrone S, et al. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol. 1986;137(9):3042–3048.
   PubMed Web of Science ®Google Scholar
• Nabeta Y, Kawaguchi S, Sahara H, et al. Recognition by cellular and humoral autologous immunity in a human osteosarcoma cell line. J Orthop Sci. 2003;8(4):554–559.
   PubMedGoogle Scholar
• Tsukahara T, Kawaguchi S, Ida K, et al. HLA-restricted specific tumor cytolysis by autologous T-lymphocytes infiltrating metastatic bone malignant fibrous histiocytoma of lymph node. J Orthop Res. 2006;24(1):94–101.
   PubMed Web of Science ®Google Scholar
• Kimura S, Kozakai Y, Kawaguchi S, et al. Clonal T-cell response against autologous pleomorphic malignant fibrous histiocytoma antigen presented by retrieved HLA-A*0206. J Orthop Res. 2008;26(2):271–278.
   PubMed Web of Science ®Google Scholar
• Mueller SN, Gebhardt T, Carbone FR, et al. Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol. 2013;31:137–161.
   PubMed Web of Science ®Google Scholar
• Kambayashi T, Assarsson E, Lukacher AE, et al. Memory CD8+ T cells provide an early source of IFN-gamma. J Immunol. 2003;170(5):2399–2408.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401(6754):708–712.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Swanson HM, Fujii N, et al. A distinct subset of self-renewing human memory CD8+ T cells survives cytotoxic chemotherapy. Immunity. 2009;31(5):834–844.
   PubMed Web of Science ®Google Scholar
• Hinks TS. MAIT cells in autoimmunity, immune mediated diseases and airways disease. Immunology. 2016;148(1):1–12.
   PubMed Web of Science ®Google Scholar
• Graef P, Buchholz VR, Stemberger C, et al. Serial transfer of single-cell-derived immunocompetence reveals stemness of CD8(+) central memory T cells. Immunity. 2014;41(1):116–126.
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17(10):1290–1297.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35(9):651–660.
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Gattinoni L, Palmer DC, et al. Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. Clin Cancer Res. 2011;17(16):5343–5352.
   PubMed Web of Science ®Google Scholar
• Fuertes Marraco SA, Soneson C, Cagnon L, et al. Long-lasting stem cell-like memory CD8+ T cells with a naive-like profile upon yellow fever vaccination. Sci Transl Med. 2015;7(282):282ra48.
   PubMed Web of Science ®Google Scholar
• Hosokawa K, Muranski P, Feng X, et al. Memory stem T cells in autoimmune disease: high frequency of circulating CD8+ memory stem cells in acquired aplastic anemia. J Immunol. 2016;196(4):1568–1578.
   PubMed Web of Science ®Google Scholar
• Takeshita M, Suzuki K, Kassai Y, et al. Polarization diversity of human CD4+ stem cell memory T cells. Clin Immunol. 2015;159(1):107–117.
   PubMed Web of Science ®Google Scholar
• Murata K, Tsukahara T, Emori M, et al. Identification of a novel human memory T cell population with the characteristics of stem-like chemo-resistance. Oncoimmunology. Forthcoming 2016;5.
   Google Scholar
• Gattinoni L, Klebanoff CA, Restifo NP. Paths to stemness: building the ultimate antitumour T cell. Nat Rev Cancer. 2012;12(10):671–684.
   PubMed Web of Science ®Google Scholar